- Conditions
- Breast Cancer
- Interventions
- ritonavir, therapeutic conventional surgery
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 2,407
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Cognitive Ability, General, Fatigue, Pain, Psychosocial Deprivation, Radiation Toxicity, Skin Abnormalities
- Interventions
- DNA analysis, gene expression analysis, enzyme-linked immunosorbent assay, flow cytometry, laboratory biomarker analysis, questionnaire administration, adjuvant therapy, assessment of therapy complications, quality-of-life assessment, 3-dimensional conformal radiation therapy, breast irradiation, external beam radiation therapy, hypofractionated radiation therapy, intensity-modulated radiation therapy, whole breast irradiation
- Genetic · Other · Procedure + 1 more
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Metastatic Breast Cancer
- Interventions
- Sorafenib, Bevacizumab, Imaging
- Drug · Other
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 10
- States / cities
- Galesburg, Illinois • Evansville, Indiana • Fort Wayne, Indiana + 5 more
- Conditions
- Breast Cancer Metastatic
- Interventions
- Amcenestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,007 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Sedona, Arizona + 128 more
- Conditions
- Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
- Interventions
- CDX-011, Capecitabine
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 57 more
- Conditions
- Advanced Solid Tumors, Metastatic Triple Negative Breast Cancer
- Interventions
- NK012 and carboplatin
- Drug
- Lead sponsor
- Nippon Kayaku Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
- Interventions
- Elacestrant, Abemaciclib
- Drug
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 11
- States / cities
- Fullerton, California • Los Angeles, California • Urbana, Illinois + 8 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
- Interventions
- Entrectinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more
- Conditions
- Breast Neoplasms
- Interventions
- Fulvestrant, Sapanisertib
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Bakersfield, California • Fullerton, California + 26 more
- Conditions
- Metastatic Breast Cancer, HER2-positive Breast Cancer
- Interventions
- BDC-1001, Pertuzumab
- Drug
- Lead sponsor
- Bolt Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Irvine, California • New York, New York • Arlington, Virginia
- Conditions
- Breast Cancer Metastases, HER2 Positive Breast
- Interventions
- 89Zr-trastuzumab, PET/CT scan, 89Zr-pertuzumab
- Radiation · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer
- Interventions
- Not listed
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Breast Cancer, Metastases
- Interventions
- Efaproxiral, Whole Brain Radiation Therapy (WBRT), Supplemental Oxygen
- Drug · Radiation · Other
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
- Conditions
- Breast Cancer
- Interventions
- Four Conversations
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- TNBC - Triple-Negative Breast Cancer, Breast Cancer
- Interventions
- Trilaciclib, Placebo, Gemcitabine, Carboplatin
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more
- Conditions
- Breast Cancer
- Interventions
- Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
- Biological · Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Hickory, North Carolina
- Conditions
- Metastatic Breast Cancer in the Liver
- Interventions
- Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine), Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
- Drug
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Cleveland, Ohio • Columbus, Ohio + 1 more
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
- Interventions
- ANG1005
- Drug
- Lead sponsor
- Angiochem Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- U.S. locations
- 2
- States / cities
- Orange, California • San Antonio, Texas
- Conditions
- Breast Cancer
- Interventions
- Ad5CMV-p53 gene, docetaxel, doxorubicin hydrochloride, conventional surgery, neoadjuvant therapy
- Biological · Drug · Procedure
- Lead sponsor
- Introgen Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, BKM120, BKM120 matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 61
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 51 more
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more
- Conditions
- Advanced Malignancies, Metastatic Cancer
- Interventions
- INCAGN01876, Epacadostat, Pembrolizumab
- Drug
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Hackensack, New Jersey